Основная статистика
| CIK | 1563880 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Trevi Therapeutics, Inc.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| August 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 14, 2025 Trevi Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38886 45-0834299 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| August 7, 2025 |
As filed with the Securities and Exchange Commission on August 7, 2025 As filed with the Securities and Exchange Commission on August 7, 2025 Registration Statement No. |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 7, 2025 Trevi Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38886 45-0834299 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| August 7, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Trevi Therapeutics, Inc. |
|
| August 7, 2025 |
Exhibit 99.1 Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates Announced positive topline results from its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with IPF Closed $115 million underwritten offering with expected cash runway into 2029 Management to host a conference call and webcast today at 4:30 p.m. ET New Have |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38886 TREVI THERAPEUTICS, INC. |
|
| June 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 11, 2025 Trevi Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38886 45-0834299 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| June 4, 2025 |
17,400,000 Shares Common Stock Table of Contents As Filed Pursuant to Rule 424(b)(5) Registration No. 333-273030 PROSPECTUS SUPPLEMENT (To Prospectus dated August 15, 2023) 17,400,000 Shares Common Stock We are offering 17,400,000 shares of our common stock in this offering. Our common stock is listed on the Nasdaq Global Market under the symbol “TRVI.” The last reported sale price for our common stock on June 3, 2025, was $5.9 |
|
| June 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2025 Trevi Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38886 45-0834299 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| June 4, 2025 |
EX-1.1 Exhibit 1.1 Execution Version Trevi Therapeutics, Inc. (a Delaware corporation) 17,400,000 Shares of Common Stock UNDERWRITING AGREEMENT June 3, 2025 Morgan Stanley & Co. LLC Leerink Partners LLC Stifel, Nicolaus & Company, Incorporated Cantor Fitzgerald & Co. as Representatives of the several Underwriters c/o Morgan Stanley & Co. LLC 1585 Broadway New York, NY 10036 c/o Leerink Partners LL |
|
| June 4, 2025 |
Trevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock EX-99.1 Exhibit 99.1 Trevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock New Haven, Conn., June 3, 2025 – Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patient |
|
| June 2, 2025 |
SUBJECT TO COMPLETION, DATED JUNE 2, 2025 424B5 Table of Contents As Filed Pursuant to Rule 424(b)(5) Registration No. 333-273030 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer to se |
|
| June 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 2, 2025 Trevi Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38886 45-0834299 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| June 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 2, 2025 Trevi Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38886 45-0834299 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 8, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 8, 2025 Trevi Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38886 45-0834299 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| May 8, 2025 |
Exhibit 99.1 Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates Completed enrollment and last patient last visit in the Phase 2b CORAL trial in IPF patients with chronic cough; topline results continue to be expected in the second quarter of 2025 Announced positive topline results from the Phase 2a RIVER trial in patients with refractory chronic cough Man |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38886 TREVI THERAPEUTICS, INC. |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| March 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 18, 2025 Trevi Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38886 45-0834299 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| March 18, 2025 |
Exhibit 99.1 Trevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates Announced positive topline data from the Phase 2a RIVER trial in patients with refractory chronic cough (RCC), making Haduvio the first therapy in clinical development to show benefit in patients with chronic cough in idiopathic pulmonary fibrosis (IPF) and RCC Completed enrollm |
|
| March 18, 2025 |
As filed with the Securities and Exchange Commission on March 18, 2025 As filed with the Securities and Exchange Commission on March 18, 2025 Registration Statement No. |
|
| March 18, 2025 |
Amended and Restated Insider Trading Policy Exhibit 19.1 Trevi Therapeutics, Inc. Insider Trading Policy 1. BACKGROUND AND PURPOSE 1.1. Why Have We Adopted This Policy? The federal securities laws prohibit any member of the Board of Directors (a “Director”), officer (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934 (the “Exchange Act”), an “executive officer”) or employee of Trevi Therapeutics, Inc. (together with its s |
|
| March 18, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Trevi Therapeutics, Inc. |
|
| March 18, 2025 |
Non-Employee Director Compensation Policy Exhibit 10.7 Non-Employee Director Compensation Program (a) Initial Stock Option Grant. Each non-employee director will receive an option under the 2019 Stock Incentive Plan (the “2019 Plan”) to purchase 60,000 shares of Common Stock upon his or her initial election or appointment to the Board. Subject to the non-employee director’s continued service as a director, employee or consultant, the opti |
|
| March 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K t UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38886 TREVI THERAPE |
|
| March 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 10, 2025 Trevi Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38886 45-0834299 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| February 14, 2025 |
EXHIBIT 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of Trevi Therapeutics, Inc. and further agree that this agreement be included as an exhibit to such filing. Each |
|
| February 14, 2025 |
EXHIBIT 99.1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of Common Stock of Trevi Therapeutics, Inc. Date: February 14, 2025 FRAZIER LIFE SCIENCES PUBLIC FUND, L.P. By: FHML |
|
| February 13, 2025 |
EX-99.A BD-DIR-RESOL 2 trviexaapr24.htm Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13G/A with respect to the beneficial ownership of shares of Common Stock of Trevi Therapeutics, Inc. is filed jointly, on behalf of each of them. Rosalind Advisors, Inc. By: Name: Steven Salamon Title: President Rosalind Master Fund L.P. By: Name: Mike McDonald Titl |
|
| January 8, 2025 |
Exhibit 99.1 Trevi Therapeutics Announces Company Updates Ahead of 14th Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference Last patient completed the Phase 2a RIVER trial in refractory chronic cough (RCC) in early January and topline results continue to be expected in the first quarter of 2025 Approximately 80% of enrollment complete in the Phase 2b CO |
|
| January 8, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 8, 2025 Trevi Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38886 45-0834299 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| December 16, 2024 |
Trevi Therapeutics Announces Pricing of $50 Million Underwritten Offering Exhibit 99.1 Trevi Therapeutics Announces Pricing of $50 Million Underwritten Offering New Haven, Conn., December 16, 2024 – Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy, Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today annou |
|
| December 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2024 Trevi Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38886 45-0834299 (State or Other Jurisdiction of Incorporation) (Commission |
|
| December 16, 2024 |
12,500,000 Shares of Common Stock Table of Contents As Filed Pursuant to Rule 424(b)(5) Registration No. 333-273030 PROSPECTUS SUPPLEMENT (To Prospectus dated August 15, 2023) 12,500,000 Shares of Common Stock We are offering 12,500,000 shares of our common stock in this offering. Our common stock is listed on the Nasdaq Global Market under the symbol “TRVI.” The last reported sale price for our common stock on December 13, 2024, |
|
| December 16, 2024 |
EX-1.1 Exhibit 1.1 Trevi Therapeutics, Inc. (a Delaware corporation) 12,500,000 Shares of Common Stock UNDERWRITING AGREEMENT December 15, 2024 Leerink Partners LLC Stifel, Nicolaus & Company, Incorporated Oppenheimer & Co. Inc. as Representatives of the several Underwriters c/o Leerink Partners LLC 1301 Avenue of the Americas, 5th Floor New York, NY 10019 c/o Stifel, Nicolaus & Company, Incorpora |
|
| December 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 12, 2024 Trevi Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38886 45-0834299 (State or Other Jurisdiction of Incorporation) (Commission |
|
| December 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 3, 2024 Trevi Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38886 45-0834299 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| November 14, 2024 |
SC 13G/A 1 tm2428137d18sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3)* Trevi Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 89532M101 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Check |
|
| November 13, 2024 |
TRVI / Trevi Therapeutics, Inc. / Rubric Capital Management LP - SC 13G/A Passive Investment SC 13G/A 1 tm2427812d20sc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Trevi Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 89532M101 (CUSIP Number) September 30, 2024 (Date of event which requires filing of this statement) Check the |
|
| November 8, 2024 |
SC 13D/A 1 nea16-trevi18901.htm NEW ENTERPRISE ASSOCIATES 16, L.P. / TREVI THERAPEUTICS, INC. - SCHEDULE 13D/A(#5) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* Trevi Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 89532M101 (CUSIP Number) Stephanie |
|
| November 6, 2024 |
Exhibit 99.1 Trevi Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates Completed enrollment of the Phase 2a RIVER trial in refractory chronic cough (RCC) with topline results expected in the first quarter of 2025 Reached 50% enrollment for the Phase 2b CORAL trial in chronic cough in idiopathic pulmonary fibrosis (IPF), with sample size re-estimation outcome exp |
|
| November 6, 2024 |
September 27, 2024 James Cassella [**] Dear Jim: We are pleased to offer you employment with Trevi Therapeutics, Inc. |
|
| November 6, 2024 |
EX-99.A 2 d869859dex99a.htm EX-99.A EXHIBIT A AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of Common Stock of Trevi Therapeutics, Inc. Date: November 6, 2024 FRAZIER LIFE SCIENCES PUBLIC |
|
| November 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 6, 2024 Trevi Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38886 45-0834299 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| November 6, 2024 |
CONSULTING SERVICES AGREEMENT This Consulting SERVICES Agreement (this “Agreement”) is made as of the date of last signature (the “Effective Date”), by and between Trevi Therapeutics, Inc. |
|
| November 6, 2024 |
SC 13G/A 1 d869859dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Trevi Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 89532M101 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38886 TREVI THERAPEUTICS, INC. |
|
| October 23, 2024 |
EX-99.A BD-DIR-RESOL 2 trviexaapr24.htm Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13G/A with respect to the beneficial ownership of shares of Common Stock of Trevi Therapeutics, Inc. is filed jointly, on behalf of each of them. Rosalind Advisors, Inc. By: Name: Steven Salamon Title: President Rosalind Master Fund L.P. By: Name: Mike McDonald Titl |
|
| October 23, 2024 |
TRVI / Trevi Therapeutics, Inc. / Rosalind Advisors, Inc. Passive Investment SC 13G/A 1 trvi13ga03sep24.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No: 03) Under the Securities Exchange Act of 1934 Trevi Therapeutics, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 89532M101 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to desig |
|
| October 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 21, 2024 Trevi Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38886 45-0834299 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| October 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 3, 2024 Trevi Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38886 45-0834299 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| October 1, 2024 |
Trevi Therapeutics Announces Appointment of James V. Cassella, Ph.D., as Chief Development Officer Exhibit 99.1 Trevi Therapeutics Announces Appointment of James V. Cassella, Ph.D., as Chief Development Officer New Haven, Conn., September 30, 2024 – Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic |
|
| October 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 27, 2024 Trevi Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38886 45-0834299 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38886 TREVI THERAPEUTICS, INC. |
|
| August 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 8, 2024 Trevi Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38886 45-0834299 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| August 8, 2024 |
Exhibit 99.1 Trevi Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates Reaffirming Clinical Trial Guidance Topline results expected in the fourth quarter of 2024 in the Phase 2a RIVER trial in refractory chronic cough (RCC) Sample size re-estimation milestone is expected in the fourth quarter of 2024 in the Phase 2b CORAL trial in chronic cough in idiopathi |
|
| July 11, 2024 |
EX-99.A BD-DIR-RESOL 2 trviexaapr24.htm Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13G/A with respect to the beneficial ownership of shares of Common Stock of Trevi Therapeutics, Inc. is filed jointly, on behalf of each of them. Rosalind Advisors, Inc. By: Name: Steven Salamon Title: President Rosalind Master Fund L.P. By: Name: Mike McDonald Titl |
|
| July 11, 2024 |
TRVI / Trevi Therapeutics, Inc. / Rosalind Advisors, Inc. Passive Investment SC 13G/A 1 trvi13ga02jul24.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No: 02) Under the Securities Exchange Act of 1934 Trevi Therapeutics, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 89532M101 (CUSIP Number) June 28, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate |
|
| June 13, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 13, 2024 Trevi Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38886 45-0834299 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 21, 2024 |
Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Trevi Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 89532M101 (CUSIP Number) Stephanie Brecher New Enterprise Associates 1954 Greenspring Drive, Suite 600 Timonium, MD 21093 (410) 842-4000 |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38886 TREVI THERAPEUTICS, INC. |
|
| May 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 7, 2024 Trevi Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38886 45-0834299 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| May 7, 2024 |
Exhibit 99.1 Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates Reaffirms guidance for the Phase 2a RIVER trial in refractory chronic cough and Human Abuse Potential (HAP) Study with topline data for each expected in the second half of 2024 Topline results continue to be expected in the first half of 2025 for the Phase 2b CORAL trial in chronic cough |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 25, 2024 |
TRVI / Trevi Therapeutics, Inc. / Rosalind Advisors, Inc. - TRVI_13GA01 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No: 01) Under the Securities Exchange Act of 1934 Trevi Therapeutics, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 89532M101 (CUSIP Number) March 31, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| April 25, 2024 |
EX-99.A BD-DIR-RESOL 2 trviexaapr24.htm EXA Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13G/A with respect to the beneficial ownership of shares of Common Stock of Trevi Therapeutics, Inc. is filed jointly, on behalf of each of them. Rosalind Advisors, Inc. By: Name: Steven Salamon Title: President Rosalind Master Fund L.P. By: Name: Mike McDonald |
|
| March 20, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 20, 2024 Trevi Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38886 45-0834299 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| March 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38886 TREVI THERAPEUT |
|
| March 20, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Trevi Therapeutics, Inc. |
|
| March 20, 2024 |
Description of Registrant’s Securities Exhibit 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of March 20, 2024, Trevi Therapeutics, Inc. (“we”, “us” or the “Company”) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our common stock, $0.001 par value per share. The following descri |
|
| March 20, 2024 |
As filed with the Securities and Exchange Commission on March 20, 2024 As filed with the Securities and Exchange Commission on March 20, 2024 Registration Statement No. |
|
| March 20, 2024 |
Dodd-Frank Compensation Recovery Policy Exhibit 97 TREVI THERAPEUTICS, INC. Dodd-Frank Compensation Recovery Policy This Compensation Recovery Policy (this “Policy”) is adopted by Trevi Therapeutics, Inc. (the “Company”) in accordance with Nasdaq Listing Rule 5608 (“Rule 5608”), which implements Rule 10D-1 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (as promulgated pursuant to Section 954 of the Dodd-Frank |
|
| March 20, 2024 |
Exhibit 99.1 Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates Reaffirms guidance for the Phase 2a RIVER trial of Haduvio in RCC patients with topline data expected in the second half of 2024 Enrollment progressing in the Phase 2b CORAL dose-ranging trial of Haduvio for the treatment of chronic cough in IPF patients Human Abuse Potentia |
|
| February 14, 2024 |
TRVI / Trevi Therapeutics, Inc. / Fairmount Funds Management LLC - SC 13G/A Passive Investment SC 13G/A 1 tm245759d3sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* TREVI THERAPEUTICS, INC. (Name of Issuer) Common Stock, Par Value $0.001 (Title of Class of Securities) 89532M101 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Check the |
|
| February 14, 2024 |
TRVI / Trevi Therapeutics, Inc. / VIKING GLOBAL INVESTORS LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d- 1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* (Amendment No. 2) Trevi Therapeutics, Inc. (Name of Issuer) Common stock, $0.001 par value per share (Title of Class of Securities) 89532M101 (C |
|
| February 14, 2024 |
SC 13G/A 1 tm246235d26sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Trevi Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 89532M101 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Check t |
|
| February 12, 2024 |
TRVI / Trevi Therapeutics, Inc. / Rubric Capital Management LP - SC 13G/A Passive Investment SC 13G/A 1 tm245464d20sc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Trevi Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 89532M101 (CUSIP Number) December 31, 2023 (Date of event which requires filing of this statement) Check the a |
|
| November 9, 2023 |
Exhibit 99.1 Trevi Therapeutics Announces Third Quarter 2023 Financial Results and Provides Business Update Initiated Phase 2a RIVER trial of Haduvio in refractory chronic cough (RCC) patients and expect topline data in the second half of 2024 Expect to initiate Phase 2b dose-ranging trial of Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) patients in the fourth q |
|
| November 9, 2023 |
h UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q h UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38886 TREVI THERAPEUTICS, INC. |
|
| November 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 9, 2023 Trevi Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38886 45-0834299 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| August 14, 2023 |
August 14, 2023 VIA EDGAR SUBMISSION Securities and Exchange Commission Division of Corporation Finance, Office of Life Sciences 100 F Street, NE Washington, DC 20549 Attention: Dillon Hagius Re: Trevi Therapeutics, Inc. |
|
| August 11, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Trevi Therapeutics, Inc. |
|
| August 11, 2023 |
As filed with the Securities and Exchange Commission on August 11, 2023 S-3/A Table of Contents As filed with the Securities and Exchange Commission on August 11, 2023 Registration No. |
|
| August 10, 2023 |
Exhibit 3.1 RESTATED CERTIFICATE OF INCORPORATION OF TREVI THERAPEUTICS, INC. (originally incorporated on March 17, 2011) FIRST: The name of the Corporation is Trevi Therapeutics, Inc. SECOND: The address of the Corporation’s registered office in the State of Delaware is Corporation Trust Center, 1209 Orange Street, in the City of Wilmington, County of New Castle, 19801. The name of its registered |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38886 TREVI THERAPEUTICS, INC. |
|
| August 10, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 10, 2023 Trevi Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38886 45-0834299 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| August 10, 2023 |
Exhibit 99.1 Trevi Therapeutics Announces Second Quarter 2023 Financial Results and Provides Business Update Plans to initiate three clinical studies in chronic cough indications for later this year remain on track Data from Phase 2 CANAL trial of chronic cough in patients with idiopathic pulmonary fibrosis published in NEJM Evidence Management to host a conference call and webcast today at 4:30 p |
|
| June 29, 2023 |
Certificate of Amendment of Restated Certificate of Incorporation of Trevi Therapeutics, Inc. Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE restated CERTIFICATE OF INCORPORATION OF TREVI THERAPEUTICS, INC. (Pursuant to Section 242 of the General Corporation Law of the State of Delaware) Trevi Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “General Corporation Law”), does hereby cert |
|
| June 29, 2023 |
Sales Agreement, dated June 29, 2023, by and between the Registrant and SVB Securities LLC EX-1.1 Exhibit 1.1 Trevi Therapeutics, Inc. Shares of Common Stock ($0.001 par value per share) SALES AGREEMENT June 29, 2023 SVB SECURITIES LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Ladies and Gentlemen: Trevi Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with SVB Securities LLC (the “Agent”), as follows: 1. Issuan |
|
| June 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 28, 2023 Trevi Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38886 45-0834299 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| June 29, 2023 |
EX-4.6 Exhibit 4.6 Form of Senior Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE |
|
| June 29, 2023 |
EX-4.4 Exhibit 4.4 TREVI THERAPEUTICS, INC. and Trustee INDENTURE Dated as of SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04 (c) 312(c) 4.04 (c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 31 |
|
| June 29, 2023 |
As filed with the Securities and Exchange Commission on June 29, 2023 Table of Contents As filed with the Securities and Exchange Commission on June 29, 2023 Registration No. |
|
| June 29, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Trevi Therapeutics, Inc. |
|
| June 29, 2023 |
Form of Subordinated Indenture EX-4.5 Exhibit 4.5 TREVI THERAPEUTICS, INC. and Trustee INDENTURE Dated as of SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE 1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4. |
|
| June 29, 2023 |
EX-4.7 Exhibit 4.7 Form of Subordinated Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER N |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 11, 2023 Trevi Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38886 45-0834299 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 11, 2023 |
As filed with the Securities and Exchange Commission on May 11, 2023 As filed with the Securities and Exchange Commission on May 11, 2023 Registration Statement No. |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38886 TREVI THERAPEUTICS, INC. |
|
| May 11, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Trevi Therapeutics, Inc. |
|
| May 11, 2023 |
Exhibit 99.1 Trevi Therapeutics Announces First Quarter 2023 Financial Results and Provides Business Update Initiating three clinical studies in chronic cough indications later this year Received Notice of Allowance for key U.S. patent for the use of oral nalbuphine ER for the treatment of chronic cough in idiopathic pulmonary fibrosis Management to host a conference call and webcast today at 4:30 |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 13, 2023 Trevi Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38886 45-0834299 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| April 14, 2023 |
Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF TREVI THERAPEUTICS, INC. TABLE OF CONTENTS ARTICLE I STOCKHOLDERS 1 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meetings 1 1.4 Record Date for Stockholder Meetings 1 1.5 Notice of Meetings 1 1.6 Voting List 1 1.7 Quorum 2 1.8 Adjournments 2 1.9 Voting and Proxies 2 1.10 Action at Meeting 2 1.11 Nomination of Directors 3 1.12 Notice of Busines |
|
| April 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 16, 2023 |
Offer Letter, dated November 4, 2022, by and between the Registrant and David Clark Exhibit 10.11 November 4, 2022 Dear David, On behalf of Trevi Therapeutics, Inc. (the “Company” or “Trevi”), I am pleased to offer you employment with the Company on the following terms. Employment. You will be hired for the position of Chief Medical Officer beginning on November 14, 2022 (the “Start Date”), reporting to Jennifer Good, CEO. You will be responsible for performing the duties and res |
|
| March 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38886 TREVI THERAPEUT |
|
| March 16, 2023 |
Exhibit 10.16 Second Amendment to Lease THIS SECOND AMENDMENT TO LEASE (“Second Amendment”) dated November 21, 2022, (“Effective Date”) by and between 195 Church Street Associates, LLC, a Connecticut limited liability corporation ("Landlord") and Trevi Therapeutics, Inc. ("Tenant"). WITNESSETH: WHEREAS, Landlord entered into a certain Indenture of Lease with Tenant dated February 6th, 2013 (the “O |
|
| March 16, 2023 |
Exhibit 99.1 Trevi Therapeutics Announces Fourth Quarter and Year End 2022 Financial Results and Provides Business Update Multiple trial initiations planned for 2023 to progress Haduvio in chronic cough indications Management to host a conference call and webcast today at 4:30 p.m. EDT New Haven, Conn., March 16, 2023 – Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical co |
|
| March 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 16, 2023 Trevi Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38886 45-0834299 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| February 15, 2023 |
TRVI / Trevi Therapeutics Inc / Rosalind Advisors, Inc. - TREVI SC 13GA Passive Investment SC 13G 1 rosalindTRVI13ga02-14-23.htm TREVI SC 13GA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No. 1) Under the Securities Exchange Act of 1934 Trevi Therapeutics, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 89532M101 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appro |
|
| February 15, 2023 |
EX-99.A BD-DIR-RESOL 2 exa.htm EXHIBIT JOINT FILING Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13G with respect to the beneficial ownership of shares of Common Stock of Trevi Therapeutics, Inc. is filed jointly, on behalf of each of them. Rosalind Advisors, Inc. By: Name: Steven Salamon Title: President Rosalind Master Fund L.P. By: Name: Mike McD |
|
| February 14, 2023 |
TRVI / Trevi Therapeutics Inc / Fairmount Funds Management LLC - SC 13G/A Passive Investment SC 13G/A 1 tm235981d7sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* TREVI THERAPEUTICS, INC. (Name of Issuer) Common Stock, Par Value $0.001 (Title of Class of Securities) 89532M101 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of This Statement) Check the |
|
| February 14, 2023 |
TRVI / Trevi Therapeutics Inc / VIKING GLOBAL INVESTORS LP - SC 13G/A Passive Investment SC 13G/A 1 brhc10047960sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d- 1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* (Amendment No. 1) Trevi Therapeutics, Inc. (Name of Issuer) Common stock, $0.001 par value per share |
|
| February 14, 2023 |
TRVI / Trevi Therapeutics Inc / ARMISTICE CAPITAL, LLC Passive Investment SC 13G/A 1 armistice-trvi123122a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* TREVI THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 89532M101 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Che |
|
| February 14, 2023 |
SC 13G/A 1 tm236584d3sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Trevi Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 89532M101 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of This Statement) Check th |
|
| February 10, 2023 |
TRVI / Trevi Therapeutics Inc / Rubric Capital Management LP - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Trevi Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 89532M101 (CUSIP Number) December 31, 2022 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant |
|
| February 10, 2023 |
TRVI / Trevi Therapeutics Inc / TPG GP A, LLC - AMENDMENT TO FORM SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 3)* Under the Securities Exchange Act of 1934 Trevi Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Titles of Class of Securities) 89532M101 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38886 TREVI THERAPEUTICS, INC. |
|
| November 10, 2022 |
Exhibit 10.1 CONSULTING SERVICES AGREEMENT This CONSULTING SERVICES AGREEMENT (this ?Agreement?) is made as of the date of last signature (the ?Effective Date?), by and between Trevi Therapeutics, Inc., a Delaware corporation with an address at 195 Church St., 14th Floor, New Haven, CT 06510 (?Trevi?) and William Forbes, an individual with an address at 1008 Heydon Court, Raleigh, NC 27614 (?Consu |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 10, 2022 Trevi Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38886 45-0834299 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 10, 2022 |
Exhibit 99.1 Trevi Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update Management to host a conference call and webcast today at 4:30 p.m. EDT New Haven, Conn., November 10, 2022 – Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic |
|
| October 7, 2022 |
TRVI / Trevi Therapeutics Inc / VIKING GLOBAL INVESTORS LP - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d- 1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* Trevi Therapeutics, Inc. (Name of Issuer) Common stock, $0.001 par value per share (Title of Class of Securities) 89532M101 (CUSIP Number) Septe |
|
| October 7, 2022 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| September 23, 2022 |
14,252,670 Shares of Common Stock Pre-Funded Warrants to Purchase 14,247,330 Shares of Common Stock Table of Contents As Filed Pursuant to Rule 424(b)(5) Registration No. 333-239499 PROSPECTUS SUPPLEMENT (To Prospectus dated July 2, 2020) 14,252,670 Shares of Common Stock Pre-Funded Warrants to Purchase 14,247,330 Shares of Common Stock We are offering 14,252,670 shares of our common stock in this offering. We are also offering, in lieu of common stock to certain investors that so choose, warran |
|
| September 23, 2022 |
Trevi Therapeutics Announces Pricing of $55 Million Public Offering Exhibit 99.1 Trevi Therapeutics Announces Pricing of $55 Million Public Offering New Haven, Conn., September 23, 2022 ? Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy, Haduvio? (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and the treatment of prurigo nodularis (P |
|
| September 23, 2022 |
Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT TREVI THERAPEUTICS, INC. Warrant Shares: Initial Exercise Date: , 2022 Issue Date: , 2022 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on o |
|
| September 23, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2022 Trevi Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38886 45-0834299 (State or Other Jurisdiction of Incorporation) (Commission |
|
| September 23, 2022 |
Exhibit 1.1 Trevi Therapeutics, Inc. (a Delaware corporation) 14,252,670 Shares of Common Stock and Pre-funded Warrants to Purchase 14,247,330 Shares of Common Stock UNDERWRITING AGREEMENT September 22, 2022 SVB Securities LLC Stifel, Nicolaus & Company, Incorporated Oppenheimer & Co. Inc. as Representatives of the several Underwriters c/o SVB Securities LLC 1301 Avenue of the Americas, 12th Floor |
|
| September 22, 2022 |
SUBJECT TO COMPLETION, DATED SEPTEMBER 22, 2022 Table of Contents As Filed Pursuant to Rule 424(b)(5) Registration No. 333-239499 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell the |
|
| September 19, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 19, 2022 Trevi Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38886 45-0834299 (State or Other Jurisdiction of Incorporation) (Commission |
|
| September 19, 2022 |
Corporate Presentation September 2022 Corporate Presentation September 2022 Forward Looking Statement Disclaimer Statements contained in this presentation and oral statements made regarding the subject of this presentation regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38886 TREVI THERAPEUTICS, INC. |
|
| August 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 11, 2022 Trevi Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38886 45-0834299 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| August 11, 2022 |
Exhibit 99.1 Trevi Therapeutics Announces Second Quarter 2022 Financial Results and Business Update Reported positive results from the Phase 2b/3 PRISM trial of Haduvio? in the treatment of Prurigo Nodularis Completed a $55 million private placement Data from the full set of subjects in the completed Phase 2 CANAL trial in chronic cough in idiopathic pulmonary fibrosis (IPF) expected in the third |
|
| June 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 29, 2022 Trevi Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38886 45-0834299 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| June 23, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 23, 2022 Trevi Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38886 45-0834299 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 16, 2022 |
Exhibit 10.1 AMENDMENT NO. 1 TO SALES AGREEMENT May 13, 2022 SVB SECURITIES LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Ladies and Gentlemen: This Amendment No. 1 to the Sales Agreement (this ?Amendment?) is entered into as of the date first written above by Trevi Therapeutics, Inc. (the ?Company?) and SVB Securities LLC (formerly known as SVB Leerink LLC) (the ?Agent?), t |
|
| May 16, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 13, 2022 Trevi Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38886 45-0834299 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 16, 2022 |
Up to $50,000,000 Common Stock As Filed Pursuant to Rule 424(b)(5) Registration No. 333-239499 PROSPECTUS SUPPLEMENT (To Prospectus Dated July 2, 2020) Up to $50,000,000 Common Stock We have entered into an amendment, dated May 13, 2022, or the Amendment, to our sales agreement with SVB Securities LLC (formerly known as SVB Leerink LLC), or SVB Securities, dated June 26, 2020, to increase the maximum aggregate offering price of |
|
| May 12, 2022 |
Offer Letter, dated January 8, 2021, by and between the Registrant and William B. Forbes Exhibit 10.1 January 8, 2021 Dear Bill, On behalf of Trevi Therapeutics, Inc. (the ?Company? or ?Trevi?), I am pleased to offer you employment with the Company on the following terms. Employment. I am pleased to offer you the position of Chief Development Officer, beginning on a mutually agreed upon date anticipated to be by the end of January (the ?Start Date?), reporting to the Chief Executive O |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38886 TREVI THERAPEUTICS, INC. |
|
| May 12, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 12, 2022 Trevi Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38886 45-0834299 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 12, 2022 |
Exhibit 99.1 Trevi Therapeutics Announces First Quarter 2022 Financial Results and Business Update Accelerated planning for next phase of development of Haduvio for the treatment of chronic cough in IPF based on results from statistically significant interim analysis of Phase 2 CANAL Trial Completed enrollment for Phase 2b/3 PRISM study in chronic pruritus in PN with data expected Q2 2022 Complete |
|
| May 9, 2022 |
May 9, 2022 VIA EDGAR SUBMISSION Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Attention: Gary Guttenberg Re: Trevi Therapeutics, Inc. |
|
| May 2, 2022 |
As filed with the Securities and Exchange Commission on May 2, 2022 As filed with the Securities and Exchange Commission on May 2, 2022 Registration Statement No. |
|
| May 2, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Trevi Therapeutics, Inc. |
|
| May 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| May 2, 2022 |
As filed with the Securities and Exchange Commission on May 2, 2022 As filed with the Securities and Exchange Commission on May 2, 2022 Registration No. |
|
| May 2, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Trevi Therapeutics, Inc. |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Trevi Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 89532M101 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600, Timonium, MD 21093 (410) 842-4000 (Name, A |
|
| April 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Trevi Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 89532M101 (CUSIP Number) April 11, 2022 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuan |
|
| April 21, 2022 |
TRVI / Trevi Therapeutics Inc / Fairmount Funds Management LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* TREVI THERAPEUTICS, INC. (Name of Issuer) Common Stock, Par Value $0.001 (Title of Class of Securities) 89532M101 (CUSIP Number) Erin O?Connor Fairmount Funds Management LLC 2001 Market Street, Suite 2501 Philadelphia, PA 19103 (267) 229-2730 (Name, Addre |
|
| April 18, 2022 |
Exhibit B EXHIBIT B POWER OF ATTORNEY KNOW ALL BY THESE PRESENTS, that the person whose signature appears below hereby constitutes and appoints Steve R. |
|
| April 18, 2022 |
Exhibit A EXHIBIT A AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of Common Stock of Trevi Therapeutics, Inc. |
|
| April 18, 2022 |
TRVI / Trevi Therapeutics Inc / Frazier Life Sciences Public Fund, L.P. - SC 13G Passive Investment SC 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| April 7, 2022 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| April 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 6, 2022 Trevi Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38886 45-0834299 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 7, 2022 |
Exhibit 99.4 Trevi Therapeutics Announces $55 Million Private Placement Priced At-the-Market Proceeds To Fund the Development of Haduvio for Chronic Cough in Idiopathic Pulmonary Fibrosis New Haven, Conn., April 7, 2022 ? Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio? (nalbuphine ER) for pruritus in prurigo nodular |
|
| April 7, 2022 |
Exhibit 99.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made and entered into as of April 6, 2022, between Trevi Therapeutics, Inc., a Delaware corporation (the ?Company?), and the purchasers signatory hereto (the ?Purchasers?). This Agreement is made pursuant to the Securities Purchase Agreement, dated as of the date hereof, between the Company and the |
|
| April 7, 2022 |
THIRD AMENDMENT LOAN AND SECURITY AGREEMENT Exhibit 99.3 THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT This Third Amendment to Loan and Security Agreement (this ?Amendment?) is entered into this 6th day of April, 2022, by and between SILICON VALLEY BANK (?Bank?) and TREVI THERAPEUTICS, INC., a Delaware corporation (?Borrower?) whose address is 195 Church Street, 14th Floor, New Haven, Connecticut 06510. RECITALS A. Bank and Borrower have e |
|
| April 7, 2022 |
Exhibit 99.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of April 6, 2022, between Trevi Therapeutics, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the Schedule of Purchasers attached hereto as Exhibit A (each, including its successors and assigns, a ?Purchaser? and collectively, the ?Purchasers?). WHEREAS, subje |
|
| March 17, 2022 |
Exhibit 99.1 Trevi Therapeutics Announces Fourth Quarter and Year End 2021 Financial Results and Business Update Interim Analysis in Phase 2 CANAL Trial Showed Primary Efficacy Endpoint of Cough Reduction in Idiopathic Pulmonary Fibrosis was Highly Statistically Significant (p-value less than 0.0001) Enrollment Ended Early Trevi to host a KOL call ?Understanding the Seriousness of Chronic Cough in |
|
| March 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38886 TREVI THERAPEUT |
|
| March 17, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 17, 2022 Trevi Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38886 45-0834299 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| March 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 16, 2022 Trevi Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38886 45-0834299 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| March 9, 2022 |
EXHIBIT 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, $0. |
|
| March 9, 2022 |
TRVI / Trevi Therapeutics Inc / Oliveira Steven Michael - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO §240.13d-2 Trevi Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 89532M101 (CUSIP Number) March 7, 2022 (Date of Event whi |
|
| March 9, 2022 |
Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13G with respect to the beneficial ownership of shares of Common Stock of Trevi Therapeutics, Inc. |
|
| March 9, 2022 |
TRVI / Trevi Therapeutics Inc / Rosalind Advisors, Inc. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Trevi Therapeutics, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 89532M101 (CUSIP Number) February 28, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is file |
|
| February 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 24, 2022 Trevi Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38886 45-0834299 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 14, 2022 |
TRVI / Trevi Therapeutics Inc / ARMISTICE CAPITAL, LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2022 |
Exhibit 99.1 Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including additional amendments thereto) with respect to the shares of Common Stock, $0.001 par value per share, of Trevi Therapeutics, Inc. This Joint |
|
| February 11, 2022 |
TRVI / Trevi Therapeutics Inc / TPG GP A, LLC - AMENDMENT TO FORM SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 2)* Under the Securities Exchange Act of 1934 Trevi Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Titles of Class of Securities) 89532M101 (CUSIP Number) January 12, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| February 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 1, 2022 Trevi Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38886 45-0834299 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| January 26, 2022 |
TRVI / Trevi Therapeutics Inc / Lundbeckfond Invest A/S - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Trevi Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 89532M101 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| January 14, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 10, 2022 Trevi Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38886 45-0834299 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| January 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 5, 2022 Trevi Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38886 45-0834299 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| November 12, 2021 |
November 12, 2021 VIA EDGAR SUBMISSION Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Attention: Daniel Crawford Re: Trevi Therapeutics, Inc. |
|
| November 10, 2021 |
Exhibit 99.1 Trevi Therapeutics Announces Third Quarter 2021 Financial Results and Business Update Phase 2b/3 PRISM (Chronic Pruritus in PN) Trial Approximately 90% Enrolled, Top-Line Data Readout Expected First Half of 2022 Phase 2 CANAL (Chronic Cough in IPF) Actively Enrolling, Top-Line Data Readout Expected First Half of 2022 Management to Host Conference Call at 4:30 pm ET New Haven, Conn., N |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38886 TREVI THERAPEUTICS, INC. |
|
| November 10, 2021 |
Exhibit 10.2 SECOND Amendment to Loan and security agreement This Second Amendment to Loan and Security Agreement (this ?Amendment?) is entered into this 13th day of August 2021, by and between SILICON VALLEY BANK (?Bank?) and TREVI THERAPEUTICS, INC., a Delaware corporation (?Borrower?) whose address is 195 Church Street, 14th Floor, New Haven, Connecticut 06510. Recitals A.Bank and Borrower have |
|
| November 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 10, 2021 Trevi Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38886 45-0834299 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 5, 2021 |
As filed with the Securities and Exchange Commission on November 5, 2021 Table of Contents As filed with the Securities and Exchange Commission on November 5, 2021 Registration No. |
|
| November 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Trevi Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 89532M101 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600, Timonium, MD 21093 (410) 842-4000 (Name, A |
|
| October 21, 2021 |
October 21, 2021 VIA EDGAR SUBMISSION Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Attention: Michael Davis and Joe McCann Re: Trevi Therapeutics, Inc. |
|
| October 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2021 Trevi Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38886 45-0834299 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| October 19, 2021 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| October 19, 2021 |
Exhibit 99.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of October 15, 2021, between Trevi Therapeutics, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively, the ?Purchasers?). WHEREAS, subject to the terms and condit |
|
| October 19, 2021 |
Exhibit 99.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made and entered into as of October 15, 2021 between Trevi Therapeutics, Inc., a Delaware corporation (the ?Company?), and the purchasers signatory hereto (the ?Purchasers?). This Agreement is made pursuant to the Securities Purchase Agreement, dated as of the date hereof, between the Company and th |
|
| October 19, 2021 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| October 15, 2021 |
As filed with the Securities and Exchange Commission on October 15, 2021 Table of Contents As filed with the Securities and Exchange Commission on October 15, 2021 Registration No. |
|
| October 8, 2021 |
Trevi Therapeutics, Inc. 195 Church Street, 14th Floor New Haven, Connecticut 06510 Trevi Therapeutics, Inc. 195 Church Street, 14th Floor New Haven, Connecticut 06510 VIA EDGAR October 8, 2021 Jane Park Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Trevi Therapeutics, Inc. Registration Statement on Form S-1 (File No. 333-259120) Dear Ms. Park: Pursuant to Rule 477 promulgated under the Securities Act of 1933 (the |
|
| October 1, 2021 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| October 1, 2021 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| October 1, 2021 |
Exhibit 99.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of September 30, 2021, between Trevi Therapeutics, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively, the ?Purchasers?). WHEREAS, subject to the terms and cond |
|
| October 1, 2021 |
Exhibit 99.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made and entered into as of September 30, 2021, between Trevi Therapeutics, Inc., a Delaware corporation (the ?Company?), and the purchasers signatory hereto (the ?Purchasers?). This Agreement is made pursuant to the Securities Purchase Agreement, dated as of the date hereof, between the Company and |
|
| October 1, 2021 |
Exhibit 99.3 Trevi Therapeutics Announces $11.8 Million Private Placement Priced At-the-Market Proceeds Will Fund the Development of Haduvio for Severe Chronic Pruritus in Prurigo Nodularis and Chronic Cough in Idiopathic Pulmonary Fibrosis New Haven, Conn., September 30, 2021 ? Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and comme |
|
| October 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2021 Trevi Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38886 45-0834299 (State or Other Jurisdiction of Incorporation) (Commis |
|
| October 1, 2021 |
Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| August 27, 2021 |
As filed with Securities and Exchange Commission on August 27, 2021 S-1 Table of Contents As filed with Securities and Exchange Commission on August 27, 2021 Registration No. |
|
| August 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 12, 2021 Trevi Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38886 45-0834299 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| August 12, 2021 |
Exhibit 99.1 Trevi Therapeutics Announces Second Quarter 2021 Financial Results and Business Update Phase 2b/3 PRISM (Chronic Pruritus in PN) Trial Approximately 80% Enrolled, Top-Line Data Readout Expected First Half of 2022 Phase 2 CANAL (Chronic Cough in IPF) Trial Recruiting, Top-Line Data Readout Expected First Half of 2022 New Haven, Conn., August 12, 2021 ? Trevi Therapeutics, Inc. (Nasdaq: |
|
| August 12, 2021 |
FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT THIS FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT (hereinafter the "First Amendment") is effective as of June 24, 2021, (the "Amendment Effective Date"), by and between Rutgers, The State University of New Jersey (hereinafter "RUTGERS") and Trevi Therapeutics, Inc. |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38886 TREVI THERAPEUTICS, INC. |
|
| August 12, 2021 |
Exhibit 10.5 June 17, 2021 Dear Lisa, On behalf of Trevi Therapeutics, Inc. (the ?Company? or ?Trevi?), I am pleased to offer you employment with the Company on the following terms. Employment. I am pleased to offer you the position of Chief Financial Officer, beginning on a mutually agreed upon date anticipated to be by the end of July (the ?Start Date?), reporting to the Chief Executive Officer |
|
| August 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 9, 2021 Trevi Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38886 45-0834299 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| July 14, 2021 |
5,170,088 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-257747 PROSPECTUS 5,170,088 Shares of Common Stock This prospectus relates to the resale, from time to time, of up to 5,170,088 shares of our common stock, par value $0.001 per share, by the selling stockholder, Lincoln Park Capital Fund, LLC, which we refer to as Lincoln Park or the selling stockholder. The shares of common s |
|
| July 12, 2021 |
TREVI THERAPEUTICS, INC. 195 Church Street, 14th Floor New Haven, CT 06510 TREVI THERAPEUTICS, INC. 195 Church Street, 14th Floor New Haven, CT 06510 July 12, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Trevi Therapeutics, Inc. Registration Statement on Form S-1 File No. 333-257747 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of |
|
| July 9, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 9, 2021 Trevi Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38886 45-0834299 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| July 9, 2021 |
Investor Presentation July 2021 Exhibit 99.1 Statements contained in this presentation and oral statements made regarding the subject of this presentation regarding matters that are not historical facts are ?forward-looking statements? within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties, and actual results may differ ma |
|
| July 7, 2021 |
As filed with the Securities and Exchange Commission on July 6, 2021 As filed with the Securities and Exchange Commission on July 6, 2021 Registration No. |
|
| July 7, 2021 |
FIRST Amendment Loan and security agreement Exhibit 99.1 FIRST Amendment to Loan and security agreement This First Amendment to Loan and Security Agreement (this ?Amendment?) is entered into this 6th day of July 2021, by and between SILICON VALLEY BANK (?Bank?) and TREVI THERAPEUTICS, INC., a Delaware corporation (?Borrower?) whose address is 195 Church Street, 14th Floor, New Haven, Connecticut 06510. Recitals A.Bank and Borrower have ente |
|
| July 7, 2021 |
As filed with Securities and Exchange Commission on July 7, 2021 Table of Contents As filed with Securities and Exchange Commission on July 7, 2021 Registration No. |
|
| July 7, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 6, 2021 Trevi Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38886 45-0834299 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| June 21, 2021 |
Exhibit 99.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this ?Agreement?), dated as of June 18, 2021, is made by and between TREVI THERAPEUTICS, INC., a Delaware corporation (the ?Company?), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with its permitted assigns, the ?Buyer?). Capitalized terms used herein and not otherwise defined here |
|
| June 21, 2021 |
Exhibit 99.1 PURCHASE AGREEMENT THIS PURCHASE AGREEMENT (the ?Agreement?), dated as of June 18, 2021, is made by and between TREVI THERAPEUTICS, INC., a Delaware corporation (the ?Company?), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the ?Investor?). Capitalized terms used herein and not otherwise defined herein are defined in Section 1 hereof. WHEREAS: Subject to t |
|
| June 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2021 Trevi Therapeutics, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38886 45-0834299 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| June 21, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 16, 2021 Trevi Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38886 45-0834299 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38886 TREVI THERAPEUTICS, INC. |
|
| May 13, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 13, 2021 Trevi Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38886 45-0834299 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 13, 2021 |
Exhibit 99.1 Trevi Therapeutics Announces First Quarter 2021 Financial Results and Business Update Phase 2b/3 PRISM (Chronic Pruritus in PN) Trial Over 70% Enrolled Phase 2 CANAL (Chronic Cough in IPF) Trial Resumes Screening at Multiple Sites Fast Track Designation Granted by FDA for Moderate to Severe Pruritus in Prurigo Nodularis (PN) New Haven, Conn., May 13, 2021 ? Trevi Therapeutics, Inc. (N |
|
| April 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 27, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 29, 2021 Trevi Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38886 45-0834299 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| March 25, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 25, 2021 Trevi Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38886 45-0834299 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| March 25, 2021 |
Exhibit 99.1 Trevi Therapeutics Announces Fourth Quarter and Year End 2020 Financial Results and Business Updates Expects to Complete Enrollment and Report Top-Line Data of the Phase 2b/3 PRISM Trial in Second Half of 2021 Cash Position Expected to Fund Operations into the Second Quarter of 2022 New Haven, Conn., March 25, 2021 ? Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmac |
|
| March 25, 2021 |
Non-Employee Director Compensation Policy Exhibit 10.7 Non-Employee Director Compensation Program (a) Initial Stock Option Grant. Each non-employee director will receive an option under the 2019 Stock Incentive Plan (the ?2019 Plan?) to purchase 40,000 shares of Common Stock upon his or her initial election or appointment to the Board. Subject to the non-employee director?s continued service as a director, employee or consultant, the opti |
|
| March 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38886 TREVI THERAPEUT |
|
| March 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 18, 2021 Trevi Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38886 45-0834299 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 1)* Under the Securities Exchange Act of 1934 Trevi Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Titles of Class of Securities) 89532M101 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| November 12, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 11, 2020 Trevi Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38886 45-0834299 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 12, 2020 |
Exhibit 99.1 Trevi Therapeutics Announces Third Quarter 2020 Financial Results and Business Update PRISM Trial of Haduvio™ for Severe Pruritus in Patients with Prurigo Nodularis Exceeds Halfway Enrollment Milestone Phase 2 Chronic Cough Trial in Patients with IPF Enrolled First New Subject Post-COVID-19 Restrictions Cash Position Expected to Fund Operations into the First Half of 2022 New Haven, C |
|
| November 12, 2020 |
Exhibit 10.1 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (this “Agreement”) dated as of August 13, 2020 (the “Effective Date”) between SILICON VALLEY BANK, a California corporation with a loan production office located at 275 Grove Street, Suite 2-200, Newton, Massachusetts 02466 (“Bank”), and TREVI THERAPEUTICS, INC., a Delaware corporation (“Borrower”), provides the terms on whi |
|
| November 12, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38886 TREVI THERAPEUTICS, INC. |
|
| October 21, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 21, 2020 Trevi Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38886 45-0834299 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| September 11, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 8, 2020 Trevi Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38886 45-0834299 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 13, 2020 |
Exhibit 99.1 TREVI THERAPEUTICS ANNOUNCES SECOND QUARTER 2020 FINANCIAL RESULTS AND BUSINESS UPDATE Announced Positive Outcome of Sample Size Re-Estimation Analysis for PRISM Trial Strong Enrollment in PRISM Trial After Lifting of COVID-19 Restrictions Announces $14 Million Term Loan - Cash Position Expected to Fund Operations into the First Half of 2022 New Haven, CT, August 13, 2020 – Trevi Ther |
|
| August 13, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 13, 2020 Trevi Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38886 45-0834299 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| August 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38886 TREVI THERAPEUTICS, INC. |
|
| July 13, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 13, 2020 Trevi Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38886 45-0834299 (State or Other Jurisdiction of Incorporation) (Commission |
|
| July 2, 2020 |
Up to $12,000,000 Common Stock 424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-239499 PROSPECTUS Up to $12,000,000 Common Stock We have entered into a sales agreement, or the Sales Agreement, with SVB Leerink LLC, or SVB Leerink, dated June 26, 2020, relating to shares of our common stock, par value $0.001 per share, offered by this prospectus. In accordance with the terms of the Sales Agreement, w |
|
| June 30, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 29, 2020 Trevi Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38886 45-0834299 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 30, 2020 |
CORRESP June 30, 2020 VIA EDGAR SUBMISSION Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Attention: Christopher Edwards Re: Trevi Therapeutics, Inc. |
|
| June 30, 2020 |
EX-99.1 Exhibit 99.1 Trevi Therapeutics Announces Election of Dominick C. Colangelo to Board of Directors Seasoned biopharmaceutical executive with over 20 years of executive leadership and corporate development experience New Haven, Conn., June 30, 2020 – Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine E |
|
| June 26, 2020 |
S-3 Table of Contents As filed with the Securities and Exchange Commission on June 26, 2020 Registration No. |
